Vect-Horus is pleased to announce that we have entered into a research evaluation and exclusive license option agreement with Servier, an independent international pharmaceutical group, to develop targeted oligonucleotide therapeutics for the treatment of central nervous system (CNS) diseases.
Under the agreement, we will leverage our proprietary VECTrans® technology platform to facilitate the transport of Servier’s oligonucleotide therapeutics across biological barriers to the brain, addressing one of the key challenges in the treatment of neurological disorders.
“This agreement further validates the potential of our VECTrans® platform to overcome delivery challenges in the CNS and expand therapeutic opportunities for patients suffering from serious neurological diseases,” said Alexandre Tokay, co-founder and CEO of Vect-Horus.